Prostate Cancer: ASCO Backs Molecular Tests for Risk Stratification

]]>(MedPage Today) -- New guidelines from the American Society for Clinical Oncology offer limited backing for molecular biomarkers as part of the risk evaluation in prostate cancer--but only when the results appear likely to influence decision...